JP2005525403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005525403A5 JP2005525403A5 JP2004500770A JP2004500770A JP2005525403A5 JP 2005525403 A5 JP2005525403 A5 JP 2005525403A5 JP 2004500770 A JP2004500770 A JP 2004500770A JP 2004500770 A JP2004500770 A JP 2004500770A JP 2005525403 A5 JP2005525403 A5 JP 2005525403A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- hydroxyestradiol
- poly
- acid
- methoxyestradiol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 43
- 238000000034 method Methods 0.000 claims 10
- 150000002159 estradiols Chemical class 0.000 claims 9
- -1 patch Substances 0.000 claims 7
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 6
- 239000002105 nanoparticle Substances 0.000 claims 6
- 229920001577 copolymer Polymers 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 229920001710 Polyorthoester Polymers 0.000 claims 4
- 239000000654 additive Substances 0.000 claims 4
- 230000000996 additive effect Effects 0.000 claims 4
- 239000011859 microparticle Substances 0.000 claims 4
- 229920000747 poly(lactic acid) Polymers 0.000 claims 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 4
- 239000002745 poly(ortho ester) Substances 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 239000003995 emulsifying agent Substances 0.000 claims 3
- 239000000463 material Substances 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- 238000013268 sustained release Methods 0.000 claims 3
- 239000012730 sustained-release form Substances 0.000 claims 3
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims 2
- DILDHNKDVHLEQB-XSSYPUMDSA-N 2-hydroxy-17beta-estradiol Chemical compound OC1=C(O)C=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 DILDHNKDVHLEQB-XSSYPUMDSA-N 0.000 claims 2
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 claims 2
- QOZFCKXEVSGWGS-ZHIYBZGJSA-N 4-hydroxy-17beta-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1O QOZFCKXEVSGWGS-ZHIYBZGJSA-N 0.000 claims 2
- BCWZIZLVBYHFES-PYEWSWHRSA-N 4-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=CC(O)=C1OC BCWZIZLVBYHFES-PYEWSWHRSA-N 0.000 claims 2
- 229920002732 Polyanhydride Polymers 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 229920000954 Polyglycolide Polymers 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 229920002988 biodegradable polymer Polymers 0.000 claims 2
- 239000004621 biodegradable polymer Substances 0.000 claims 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004945 emulsification Methods 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 239000010419 fine particle Substances 0.000 claims 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 2
- 239000011976 maleic acid Substances 0.000 claims 2
- 239000003607 modifier Substances 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 235000006408 oxalic acid Nutrition 0.000 claims 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 claims 2
- 229920001308 poly(aminoacid) Polymers 0.000 claims 2
- 229920000117 poly(dioxanone) Polymers 0.000 claims 2
- 229940065514 poly(lactide) Drugs 0.000 claims 2
- 229920001610 polycaprolactone Polymers 0.000 claims 2
- 239000004632 polycaprolactone Substances 0.000 claims 2
- 229920000515 polycarbonate Polymers 0.000 claims 2
- 239000004417 polycarbonate Substances 0.000 claims 2
- 229920002721 polycyanoacrylate Polymers 0.000 claims 2
- 229920006149 polyester-amide block copolymer Polymers 0.000 claims 2
- 229920001451 polypropylene glycol Polymers 0.000 claims 2
- 239000004814 polyurethane Substances 0.000 claims 2
- 229920002635 polyurethane Polymers 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- HXSHBEIVXXJJIJ-MHEUWTTISA-N (8R,9S,13S,14S)-15-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@]4(C)C(O)CC(OC)[C@H]4[C@@H]3CCC2=C1 HXSHBEIVXXJJIJ-MHEUWTTISA-N 0.000 claims 1
- UDNMPVOWUKCNKT-CRWCAEIDSA-N 1-[(8R,9S,13S,14S)-2,3,17-trihydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound C(C)(=O)C1(CC[C@@H]2[C@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C(=C3)O)O UDNMPVOWUKCNKT-CRWCAEIDSA-N 0.000 claims 1
- COTYGJHCZGLIGS-CNNNQZGYSA-N 1-[(8R,9S,13S,14S)-3,17-dihydroxy-2-methoxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound C(C)(=O)C1(CC[C@@H]2[C@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C(=C3)OC)O COTYGJHCZGLIGS-CNNNQZGYSA-N 0.000 claims 1
- UOOMQNNFAQAHTM-XQIDPSSHSA-N 1-[(8R,9S,13S,14S)-3,17-dihydroxy-4-methoxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound C(C)(=O)C1(CC[C@@H]2[C@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C(=C(O)C=C3)OC)O UOOMQNNFAQAHTM-XQIDPSSHSA-N 0.000 claims 1
- BXNCUWSDFICGJS-DFJNYNKPSA-N 1-[(8R,9S,13S,14S)-3,4,17-trihydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound C(C)(=O)C1(CC[C@@H]2[C@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C(=C(O)C=C3)O)O BXNCUWSDFICGJS-DFJNYNKPSA-N 0.000 claims 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 1
- 241000272173 Calidris Species 0.000 claims 1
- 208000034423 Delivery Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- BFHINCBWOUVXDY-YNBCETFXSA-N [(8R,9S,13S,14S)-3,17-dihydroxy-2-methoxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-phenylmethanone Chemical compound C(C1=CC=CC=C1)(=O)C1(CC[C@@H]2[C@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C(=C3)OC)O BFHINCBWOUVXDY-YNBCETFXSA-N 0.000 claims 1
- OECMUPMGAKHJOU-JRTFQXGXSA-N [(8R,9S,13S,14S)-3,17-dihydroxy-4-methoxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-phenylmethanone Chemical compound C(C1=CC=CC=C1)(=O)C1(CC[C@@H]2[C@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C(=C(O)C=C3)OC)O OECMUPMGAKHJOU-JRTFQXGXSA-N 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000001361 adipic acid Substances 0.000 claims 1
- 235000011037 adipic acid Nutrition 0.000 claims 1
- 238000000137 annealing Methods 0.000 claims 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 150000001991 dicarboxylic acids Chemical class 0.000 claims 1
- 208000028208 end stage renal disease Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 229960005309 estradiol Drugs 0.000 claims 1
- 229930182833 estradiol Natural products 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 239000000374 eutectic mixture Substances 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 239000010408 film Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- 150000008040 ionic compounds Chemical class 0.000 claims 1
- 239000002563 ionic surfactant Substances 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 239000003094 microcapsule Substances 0.000 claims 1
- 239000002088 nanocapsule Substances 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- YBHOWJOWDAEAPD-MBWVUCGFSA-N phenyl-[(8R,9S,13S,14S)-2,3,17-trihydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]methanone Chemical compound C(C1=CC=CC=C1)(=O)C1(CC[C@@H]2[C@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C(=C3)O)O YBHOWJOWDAEAPD-MBWVUCGFSA-N 0.000 claims 1
- 150000003904 phospholipids Chemical group 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000473 propyl gallate Substances 0.000 claims 1
- 235000010388 propyl gallate Nutrition 0.000 claims 1
- 229940075579 propyl gallate Drugs 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 230000037317 transdermal delivery Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 230000009677 vaginal delivery Effects 0.000 claims 1
- 230000006492 vascular dysfunction Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37749002P | 2002-05-03 | 2002-05-03 | |
| PCT/US2003/012727 WO2003092585A2 (en) | 2002-05-02 | 2003-04-25 | Controlled release compositions of estradiol metabolites |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005525403A JP2005525403A (ja) | 2005-08-25 |
| JP2005525403A5 true JP2005525403A5 (https=) | 2006-06-08 |
Family
ID=29401508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004500770A Pending JP2005525403A (ja) | 2002-05-03 | 2003-04-25 | エストラジオール代謝産物の徐放性組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20060083778A1 (https=) |
| EP (1) | EP1507514B1 (https=) |
| JP (1) | JP2005525403A (https=) |
| AT (1) | ATE353632T1 (https=) |
| AU (1) | AU2003231082A1 (https=) |
| DE (1) | DE60311801T2 (https=) |
| WO (1) | WO2003092585A2 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040157816A1 (en) * | 2002-08-26 | 2004-08-12 | Girouard Michael P. | Monounsaturated fatty acids and perhydrocyclopentanophenanthrene nucleus combination molecules, and their precursors, and the use of all of these as weight-loss agents |
| EP1829529A1 (en) * | 2002-05-03 | 2007-09-05 | PR Pharmaceuticals, Inc. | Controlled release compositions of estradiol metabolites |
| WO2004012664A2 (en) * | 2002-08-02 | 2004-02-12 | University Of Pittsburgh | Administration of estradiol metabolites for inhibition of drug-induced nephrotoxicity |
| ES2427092T3 (es) | 2003-04-10 | 2013-10-28 | Evonik Corporation | Un método para la producción de micropartículas a base de emulsión |
| CN1852687B (zh) | 2003-07-15 | 2014-01-22 | 赢创有限公司 | 控释组合物的制备方法 |
| JP5165240B2 (ja) * | 2003-07-23 | 2013-03-21 | ピーアール ファーマシューティカルズ， インコーポレイテッド | 徐放組成物 |
| WO2006088647A1 (en) * | 2005-02-17 | 2006-08-24 | Medivas, Llc | Polymer particle delivery compositions and methods of use |
| US20050106214A1 (en) * | 2003-11-14 | 2005-05-19 | Guohua Chen | Excipients in drug delivery vehicles |
| US20060057216A1 (en) * | 2004-09-15 | 2006-03-16 | Salamone Joseph C | Low-obscuration image transmitting particulate ocular therapeutic formulations |
| US20090280064A1 (en) * | 2005-06-24 | 2009-11-12 | Rao Papineni | Transdermal delivery of optical, spect, multimodal, drug or biological cargo laden nanoparticle(s) in small animals or humans |
| US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
| SG177184A1 (en) | 2006-12-01 | 2012-01-30 | Anterios Inc | Amphiphilic entity nanoparticles |
| SG179457A1 (en) | 2006-12-01 | 2012-04-27 | Anterios Inc | Peptide nanoparticles and uses therefor |
| CN101765423B (zh) | 2007-05-31 | 2014-08-06 | 安特里奥公司 | 核酸纳米粒子和其用途 |
| EP2196194B1 (en) * | 2007-09-10 | 2017-08-09 | M Technique Co., Ltd. | Process for producing biological ingesta and biological ingesta obtained thereby |
| US20120015017A1 (en) * | 2009-05-19 | 2012-01-19 | Nyden Bo Magnus | Slow releasing microcapsules containing an active substance |
| US20110275686A1 (en) * | 2009-12-11 | 2011-11-10 | Biolitec, Inc. | Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt) |
| CN101953774B (zh) * | 2010-09-17 | 2011-11-23 | 郑州大学 | 2-甲氧基雌二醇可注射水凝胶植入剂 |
| US8580294B2 (en) | 2010-10-19 | 2013-11-12 | International Partnership For Microbicides | Platinum-catalyzed intravaginal rings |
| US8633178B2 (en) | 2011-11-23 | 2014-01-21 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| KR102005579B1 (ko) * | 2012-11-19 | 2019-07-30 | 가톨릭대학교 산학협력단 | 세포배양용 다공성 지지체 및 이의 제조방법 |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| WO2014164723A1 (en) * | 2013-03-12 | 2014-10-09 | The Johns Hopkins University | Short-chain fatty acid hexosamine analogs and their use in tissue engineering applications |
| GB2521334B (en) * | 2013-08-21 | 2018-06-20 | Univ Swansea | Topical drug patch including microspheres |
| US10137031B2 (en) | 2013-11-14 | 2018-11-27 | International Partnership For Microbicides, Inc. | Combination therapy intravaginal rings |
| CL2013003807A1 (es) * | 2013-12-31 | 2014-07-11 | Univ Santiago Chile | Dispositivos de tubos pequeños de silicona que contienen nanopartículas y micropartículas de zeolitas como agentes de liberación prolongada y controlada, cargadas con 2-metoxiestradiol y suspendidas en un medio oleoso que también contiene 2-metoxiestradiol. |
| EP3145489A1 (en) | 2014-05-22 | 2017-03-29 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| BR112017016424B1 (pt) | 2015-03-31 | 2022-10-25 | Merck Sharp & Dohme B.V. | Aplicador de anel vaginal, e, kit |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| MX2019005833A (es) | 2016-11-21 | 2019-10-30 | Eirion Therapeutics Inc | Administracion transdermica de agentes grandes. |
| WO2020189886A2 (ko) * | 2019-03-19 | 2020-09-24 | (주)리젠바이오텍 | 스테로이드계 약물을 포함하는 생분해성 고분자 미세입자 및 이의 제조 방법 |
| CN113509448A (zh) * | 2020-07-02 | 2021-10-19 | 安徽中医药大学 | 一种可生物降解控释长效植入片及其制备方法 |
| CN116059181A (zh) * | 2022-09-26 | 2023-05-05 | 上海交通大学医学院附属新华医院 | 一种纳米药物递送系统 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288496A (en) * | 1990-05-15 | 1994-02-22 | Stolle Research & Development Corporation | Growth promoters for animals |
| HU222501B1 (hu) * | 1991-06-28 | 2003-07-28 | Endorecherche Inc. | MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására |
| US5643595A (en) * | 1992-11-24 | 1997-07-01 | Alkermes Controlled Therapeutics Inc. Ii | Growth promoters for animals |
| MX9700850A (es) * | 1995-06-09 | 1997-09-30 | Euro Celtique Sa | Formulaciones y metodos para proporcionar anestesia local prolongada. |
| US5855913A (en) * | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US6495579B1 (en) * | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
| DE69819145T2 (de) * | 1997-04-17 | 2004-08-19 | Amgen Inc., Thousand Oaks | Bioabbaubare mikropartikeln mit verzögerter wirkstofffreisetzung |
| AUPQ342599A0 (en) * | 1999-10-14 | 1999-11-04 | University Of Melbourne, The | Conjugates and uses thereof |
| US6743446B2 (en) * | 1999-12-15 | 2004-06-01 | The Ohio State University Research Foundation | Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers |
| EP1418876A4 (en) * | 2001-08-17 | 2007-07-11 | Univ Pittsburgh | ADMINISTRATION OF OSTRADIOL METABOLITES FOR THE TREATMENT OR PREVENTION OF ADIPOSITAS, METABOLIC SYNDROME, DIABETES AND VASCULAR AND KIDNEY DISEASES |
-
2003
- 2003-04-25 WO PCT/US2003/012727 patent/WO2003092585A2/en not_active Ceased
- 2003-04-25 US US10/513,542 patent/US20060083778A1/en not_active Abandoned
- 2003-04-25 JP JP2004500770A patent/JP2005525403A/ja active Pending
- 2003-04-25 AT AT03724207T patent/ATE353632T1/de not_active IP Right Cessation
- 2003-04-25 EP EP03724207A patent/EP1507514B1/en not_active Expired - Lifetime
- 2003-04-25 AU AU2003231082A patent/AU2003231082A1/en not_active Abandoned
- 2003-04-25 DE DE60311801T patent/DE60311801T2/de not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005525403A5 (https=) | ||
| CN1224380C (zh) | 减少微颗粒中残留有机溶剂的方法和所述微颗粒在制备药物中的用途 | |
| Mao et al. | Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres | |
| Meng et al. | W/O/W double emulsion technique using ethyl acetate as organic solvent: effects of its diffusion rate on the characteristics of microparticles | |
| JP4903344B2 (ja) | 選択ポリマー分子量を有するマイクロ粒子を調製する方法 | |
| JP2018162283A (ja) | 粘液浸透性被覆粒子、組成物、医薬組成物、医薬製剤、及びそれらの形成方法 | |
| Patel et al. | Biodegradable polymers: emerging excipients for the pharmaceutical and medical device industries | |
| CN112972388B (zh) | 卡利拉嗪释放制剂 | |
| JP7500659B2 (ja) | 架橋粒子 | |
| WO1994010982A1 (fr) | Microsphere a liberation prolongee contenant un antipshychotique et procede de production | |
| CN103298459A (zh) | 用于直接在包装表面上形成药用产品的方法和系统 | |
| CN102481264A (zh) | 包含聚噁唑啉和生物活性剂的药物递送系统 | |
| CN101137347A (zh) | 包含水凝胶基质和微载体的活性物质递送系统 | |
| CN106344521A (zh) | 一种高载药量可生物降解布比卡因微球的制备及其应用 | |
| US20220040201A1 (en) | Liquid polymer delivery system for extended administration of drugs | |
| WO2003037337A1 (en) | Depot formulations of iloperidone and a star polymer | |
| KR101900482B1 (ko) | 미립구형 서방출 주사제 및 그의 제조방법 | |
| US10874612B2 (en) | Biodegradable polymer microsphere compositions for parenteral administration | |
| JP6720447B2 (ja) | 酸感受性薬剤の送達のための薬剤送達系 | |
| JP5851518B2 (ja) | 生理活性ペプチドを含む微小粒子及びその製造方法、及びそれらを含む薬剤学的組成物 | |
| WO2003097015A1 (en) | Short chain polymer for enhancing the bioadhesiveness of polymers on mucosal membrane | |
| CN114099448A (zh) | 一种均一聚合物微球的制备方法 | |
| JPS63233926A (ja) | ペプチド含有マイクロカプセルおよびその製造法 | |
| KR102383448B1 (ko) | 락트산 또는 글리콜산을 포함하는 미립구형 서방출 제제 및 그의 제조방법 | |
| JP2024507528A5 (https=) |